Published in Scand J Clin Lab Invest on June 01, 1977
Hepatic ethanol elimination kinetics in patients with cirrhosis. Scand J Gastroenterol (2009) 1.41
Hepatic uptake and metabolism of galactose can be quantified in vivo by 2-[18F]fluoro-2-deoxygalactose positron emission tomography. Am J Physiol Gastrointest Liver Physiol (2008) 1.22
The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study. BMC Gastroenterol (2009) 0.99
Hepatic galactose metabolism quantified in humans using 2-18F-fluoro-2-deoxy-D-galactose PET/CT. J Nucl Med (2011) 0.98
Determination of hepatic galactose elimination capacity using 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT: reproducibility of the method and metabolic heterogeneity in a normal pig liver model. Scand J Gastroenterol (2010) 0.90
Regional metabolic liver function measured in patients with cirrhosis by 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT. J Hepatol (2013) 0.87
Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease. Scand J Gastroenterol (2010) 0.75
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scand J Clin Lab Invest Suppl (1966) 2.03
Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology (1984) 1.95
Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology (1985) 1.86
Updating prognosis and therapeutic effect evaluation in cirrhosis with Cox's multiple regression model for time-dependent variables. Scand J Gastroenterol (1986) 1.57
A simple method for determination of antipyrine clearance. Clin Pharmacol Ther (1982) 1.41
Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology (1980) 1.33
Michaelis-Menten kinetics of galactose elimination by the isolated perfused pig liver. Am J Physiol (1976) 1.31
Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis (1986) 1.29
Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone. Gastroenterology (1981) 1.25
Use of a prognostic index in evaluation of liver transplantation for primary biliary cirrhosis. Transplantation (1986) 1.24
The Lugano statements on controlled clinical trials. J Int Med Res (1987) 1.23
Clearance of antipyrine-dependence of quantitative liver function. Eur J Clin Invest (1974) 1.19
Treatment of acute viral hepatitis with (+)-cyanidanol-3. Lancet (1977) 1.18
Galactose elimination capacity as a prognostic index in patients with fulminant liver failure. Gut (1976) 1.13
Intermittent intrahepatic cholestasis of unknown etiology in five young males from the Faroe Islands. Acta Med Scand (1969) 1.10
Prognostic factors in cirrhosis identified by Cox's regression model. Hepatology (1983) 1.06
Enzymatic elimination of substrates flowing through the intact liver. J Theor Biol (1976) 1.06
Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial. Gastroenterology (1980) 1.06
Glycerol metabolism in the human liver: inhibition by ethanol. Science (1965) 1.03
Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. Gastroenterology (1993) 1.03
Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. Gut (1985) 0.98
High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs (1992) 0.97
Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol (2001) 0.96
Fulminant hepatic failure. Clin Gastroenterol (1981) 0.93
Autoprotection in acetaminophen intoxication in rats: the role of liver regeneration. Pharmacol Toxicol (2001) 0.92
The epidemiology of the gastrointestinal randomized clinical trial. N Engl J Med (1977) 0.91
The physiologic basis for clearance measurements in hepatology. Scand J Gastroenterol (1979) 0.90
Changes of laboratory variables with time in cirrhosis: prognostic and therapeutic significance. Hepatology (1985) 0.89
Determination of the hepatic blood flow in man by simultaneous use of five test substances measured in two parts of the liver. Scand J Clin Lab Invest (1965) 0.89
Pig liver perfusion in the treatment of acute hepatic failure. Scand J Gastroenterol Suppl (1971) 0.89
Liver function and blood flow in normal man during infusion of vasopressin. Scand J Clin Lab Invest (1969) 0.89
Main causes of death in cirrhosis. Scand J Gastroenterol (1983) 0.88
Conversion of micronodular cirrhosis into macronodular cirrhosis. Hepatology (1983) 0.88
Plasma cyclic AMP and total catecholamines during acute myocardial infarction in man. Eur J Clin Invest (1974) 0.88
Prediction of hepatic encephalopathy in paracetamol overdose: a prospective and validated study. Scand J Gastroenterol (1999) 0.87
Prediction of fatality in fulminant hepatic failure. Scand J Gastroenterol (1984) 0.85
Serum Gc-globulin in the early course of multiple trauma. Crit Care Med (1998) 0.85
Fine-resolution mapping by haplotype evaluation: the examples of PFIC1 and BRIC. Hum Genet (1999) 0.84
Albumin synthesis rate as a measure of liver function in patient with cirrhosis. Acta Med Scand (1967) 0.83
Hepatic plasma flow estimated according to Fick's principle in patients with hepatic encephalopathy: evaluation of indocyanine green and D-sorbitol as test substances. Hepatology (1998) 0.83
Hepatic, renal, and total body galactose elimination in the pig. Am J Physiol (1993) 0.83
The hepatic metabolism of ethanol in patients with cirrhosis of the liver. Scand J Clin Lab Invest (1969) 0.83
Effects of growth hormone and insulin-like growth factor-I singly and in combination on in vivo capacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats. Hepatology (1997) 0.82
Effect of dietary protein on the capacity of urea synthesis in rats. Horm Metab Res (1990) 0.82
Anti-inflammatory treatment of chronic active liver disease. Prog Liver Dis (1970) 0.82
Systemic vascular resistance during high-volume plasmapheresis in patients with fulminant hepatic failure: relationship with oxygen consumption. Eur J Gastroenterol Hepatol (1995) 0.82
Continuous reaction time in patients with hepatic encephalopathy. A quantitative measure of changes in consciousness. Scand J Gastroenterol (1981) 0.82
Hepatic blood flow and splanchnic oxygen consumption in patients with liver failure. Effect of high-volume plasmapheresis. Hepatology (1999) 0.82
Treatment of duodenal ulcer. Randomized clinical trials of a decade (1964 to 1974). Gastroenterology (1977) 0.81
A liver factor increasing glucose uptake in rat hindquarters. J Hepatol (1994) 0.81
The effects of azathioprin in patients with cirrhosis of the liver. Scand J Gastroenterol Suppl (1970) 0.81
Effects of LPS on transport of indocyanine green and alanine uptake in perfused rat liver. Am J Physiol (1999) 0.81
Early features of primary biliary cirrhosis: an analysis of 85 patients. Am J Gastroenterol (1985) 0.81
Liver function and blood flow at high altitude. J Appl Physiol (1970) 0.80
The relation between function and perfusion of the isolated pig liver. Scand J Gastroenterol Suppl (1971) 0.80
The prognostic value of laboratory tests in liver disease. Scand J Gastroenterol Suppl (1973) 0.80
Functional loss of cerebral blood flow autoregulation in patients with fulminant hepatic failure. J Hepatol (1995) 0.79
Kinetics of glucose metabolism in relation to insulin concentrations in patients with alcoholic cirrhosis and in healthy persons. Gastroenterology (1984) 0.79
Temporal profile of total, bound, and free Gc-globulin after acetaminophen overdose. Liver Transpl (2001) 0.79
Heterogeneity of splanchnic vascular transit times in man. Clin Physiol (1983) 0.79
Prognostic evaluation in alcoholic cirrhosis. Acta Med Scand Suppl (1985) 0.79
The function of the isolated perfused and the in vivo pig liver. Scand J Gastroenterol Suppl (1971) 0.79
A therapeutic index that predicts the individual effects of prednisone in patients with cirrhosis. Gastroenterology (1985) 0.79
Splanchnic galactose uptake in patients with cirrhosis during continuous infusion. Clin Physiol (1983) 0.79
The function of the isolated pig liver cross-perfused with anhepatic pigs and patients with liver failure. Scand J Gastroenterol Suppl (1971) 0.79
The diagnostic use of specific determination of unconjugated bilirubin. Scand J Clin Lab Invest (1968) 0.78
Galactose removal kinetics during hypoxia in perfused pig liver: reduction of Vmax, but not of intrinsic clearance Vmax/Km. Eur J Clin Invest (1990) 0.78
Serum bilirubin studies in patients with intermittent intrahepatic cholestasis. Gut (1967) 0.78
Effects of growth hormone on steroid-induced increase in ability of urea synthesis and urea enzyme mRNA levels. Am J Physiol (1998) 0.78
Specific determination of serum bilirubin diglucuronide in patients with hepato-biliary diseases. Scand J Clin Lab Invest (1969) 0.78
Cerebral blood flow, oxygen metabolism and transcranial Doppler sonography during high-volume plasmapheresis in fulminant hepatic failure. Eur J Gastroenterol Hepatol (1996) 0.78
Glucoregulation in acute liver failure. Eur J Clin Invest (1986) 0.78
The present status of corticosteroid therapy in liver diseases. Scand J Gastroenterol (1969) 0.78
Growth factors and gene expression in cultured rat hepatocytes. J Hepatol (1999) 0.78
Significance of suspected "chronic aggressive hepatitis" in acute hepatitis. Gastroenterology (1977) 0.78
Diagnostic procedures in the evaluation of hepatic diseases. Functional evaluation of the hepatocyte. Lab Res Methods Biol Med (1983) 0.78
Diagnostic value of routine liver tests. Clin Chem (1975) 0.78
GH decreases hepatic amino acid degradation after small bowel resection in rats without enhancing bowel adaptation. Am J Physiol Gastrointest Liver Physiol (2000) 0.78
Admission levels of serum Gc-globulin: predictive value in fulminant hepatic failure. Hepatology (1996) 0.77
High-volume plasmapheresis and acute liver transplantation in fulminant hepatic failure. Transplant Proc (1994) 0.77
The effect of hyperosmotic solutions on the hepatic blood flow. Clin Physiol (1993) 0.77
Splanchnic galactose uptake in patients with cirrhosis following single injection. Clin Physiol (1983) 0.77
Degradation of albumin and IgG at high altitude. J Appl Physiol (1970) 0.77
Azathioprine and prognosis in primary biliary cirrhosis. Gastroenterology (1986) 0.77
Reduced serum Gc-globulin concentrations in patients with fulminant hepatic failure: association with multiple organ failure. Crit Care Med (1997) 0.76
A numerical taxonomic analysis of symptoms and signs in 400 patients with cirrhosis of the liver. Comput Biomed Res (1970) 0.76
The causes of death in prednisone treated and control patients with cirrhosis. Scand J Gastroenterol Suppl (1970) 0.76
Liver function, histology, and cytochemistry in man following halothane and cyclopropane anaesthesia. Acta Med Scand (1966) 0.76
The clinical significance of classifications of cirrhosis. A comparison between conventional criteria and numerical taxonomy. Scand J Gastroenterol (1976) 0.76
Effects of a Brussels sprouts extract on oxidative DNA damage and metabolising enzymes in rat liver. Food Chem Toxicol (2001) 0.75
Lethal effect of feeding rats on galactose-ethanol. Nature (1969) 0.75
Screening of Danish blood donors for hepatitis B surface antigen using a third generation technique. Br Med J (Clin Res Ed) (1985) 0.75
Aspects of hepatic hypoxia: observations on the isolated, perfused pig liver. Bull N Y Acad Med (1975) 0.75
Albumin and IgG turnover studies in patients with cirrhosis. Scand J Gastroenterol Suppl (1970) 0.75
A biomedical computer programme system for controlled trials. Scand J Gastroenterol Suppl (1970) 0.75
Increased cellular immunological response in patients with chronic liver disease. Scand J Gastroenterol Suppl (1970) 0.75
The prognostic value of clinical and laboratory data in patients with cirrhosis. Scand J Gastroenterol Suppl (1970) 0.75
A methodologic study of the bromsulfalein method for hepatic blood flow determinations. Scand J Clin Lab Invest (1965) 0.75
[The prognosis in fulminant hepatitis]. Ugeskr Laeger (1985) 0.75